Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIONA OLE open-label extension of finerenone in children with chronic kidney disease and proteinuria
MOH_2022-12-19_012242Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of finerenone in chronic kidney disease (CKD), sponsored by Bayer. Started Dec 2022; status: active, not recruiting.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on MOH_2022-12-19_012242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-19_012242.